Quarterly Result15 May 2026, 01:26 pm
Solara: Q4'26 Revenue Highest in 8 Quarters, Up 40% YoY
AI Summary
Solara Active Pharma Sciences Ltd reported strong Q4'26 results, driven by base business momentum despite headwinds in the commodity Ibuprofen business. Overall Q4'26 performance reflects a sequential growth of 12% and YoY growth of 40%, achieving the highest revenue, gross margin, and EBITDA in the last eight quarters. The base business demonstrated superior profitability with a ~26% EBITDA margin and ~54% gross margin. The company has appointed bankers to evaluate strategic options for the Ibuprofen business due to persistent weak profitability.
Key Highlights
- Base business revenue grew 24% QoQ and 36% YoY in Q4'26.
- Base business EBITDA grew 53% QoQ and 16% YoY.
- Q4'26 overall revenue reflects 12% sequential growth and 40% YoY growth.
- Company recorded highest Revenue, Gross margin & EBITDA in the last eight quarters.
- Strategic options being evaluated for the Ibuprofen business due to weak profitability.